Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
July 2017 By Marcus Low Editor's note: This version has been modified from the original print version on August 7, 2017 to reflect recent updates and clarify the status of access to delamanid. INTRODUCTION Arguably, the most critical questions in…
July 2017 By Lindsay McKenna INTRODUCTION An unacceptable disparity exists between the estimated burden of tuberculosis (TB) in children and the number actually diagnosed and put on TB treatment each year. In 2015, just 384,300 of an estimated one million…
July 2017 By Mike Frick INTRODUCTION One of the tuberculosis (TB) field’s most often voiced truisms has been that one-third of humanity is infected with Mycobacterium tuberculosis (MTB), the causative agent of TB disease. This estimate is invoked so frequently…
July 2017 By Erica Lessem INTRODUCTION Diagnosing tuberculosis (TB) is the first step to being able to treat it and prevent transmission. New guidelines from the World Health Organization (WHO) note that diagnosis should be “available free of charge to…
Original air date: June 6, 2017 - In November, Ministers of Health and Finance from 56 of the most high burden TB countries will gather in Moscow for the first ever Ministerial Conference on TB. This webinar provided participants with specific skills…
TAG’s strong financial health and commitment to accountability and transparency have earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator.
Original air date - MAY 30, 2017 Inadequate funding for research has contributed to programs' inability to adequately address tuberculosis (TB), the leading infectious killer in the world. The first-ever Ministerial Conference on ending TB will be held in Moscow…
Statement condemning passage of the American Health Care Act (AHCA) today by the House of Representatives and calls for critical community action as the dangerous bill now heads to Senate.
With growing bipartisan support for feasible measures to control skyrocketing prescription medication costs, a Health Affairs Blog post published today describes four proposals to strengthen and modernize cost control measures that already exist in the United States.